ReviewIntensive care medicine2025
Life-threatening immune-related adverse events in the intensive care unit: a narrative review.
Review in Intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Triple M overlap syndrome in the intensive care unit: differential diagnosis and management.Critical care (London, England) · 2026Review
- Case Report: Sintilimab-associated acute interstitial nephritis in a patient with severe thrombocytopenia: clinical diagnosis and treatment strategy when renal biopsy is contraindicated.Frontiers in medicine · 2026Article
- Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management.Frontiers in medicine · 2026Review
- Mechanistic drivers of PD-L1/CTLA-4 checkpoint inhibitor-associated immune toxicity and systemic organ injury.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by significantly improving survival across various malignancies. However, they are associated with immune-related adverse events (irAEs), resulting from excessive immune activation. Some irAEs can be life-threatening and require intensive care unit (ICU) management. These toxicities involve cardiovascular, pulmonary, hepatic, gastrointestinal, neurologic, endocrine, and hematologic systems and often occur early in the ICI course. As ICI become increasingly integrated into earlier phases of cancer care, intensivists must be prepared to manage irAEs.
designNarrative review objectives: To summarize the evolving evidence on the epidemiology, diagnosis, and management of severe irAEs requiring intensive care by looking for the most relevant articles up to August 2025. The review emphasizes (1) the rationale and timing for immunosuppression beyond corticosteroids, (2) the integration of hemodynamic and organ support strategies, and (3) the importance of multidisciplinary coordination between oncology and critical care teams.
resultsEarly recognition, structured diagnostic evaluation, and multidisciplinary management are key to optimizing outcomes. Although overall mortality remains high-particularly in myocarditis and multisystem involvement-timely diagnosis and individualized immunosuppressive therapy can improve survival. Rechallenge with ICIs may be cautiously considered in selected patients after full clinical recovery and comprehensive risk assessment. This review aims to support intensivists facing this emerging clinical scenario by synthesizing current evidence and practical strategies for balancing immune modulation with oncologic efficacy in the ICU setting.
Indexed as
Identifiers
41123622What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.